Cargando…
Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the most frequent primitive cancer of the liver, accounting for 90% of all recorded cases. HCC is the third most common cause of cancer-related death, with a 5-year survival rate of just 3%. In terms of the advanced stages, systemic treatments have a...
Autores principales: | Laface, Carmelo, Fedele, Palma, Maselli, Felicia Maria, Ambrogio, Francesca, Foti, Caterina, Molinari, Pasquale, Ammendola, Michele, Lioce, Marco, Ranieri, Girolamo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406380/ https://www.ncbi.nlm.nih.gov/pubmed/36011021 http://dx.doi.org/10.3390/cancers14164028 |
Ejemplares similares
-
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
por: Laface, Carmelo, et al.
Publicado: (2023) -
Intra-Arterial Infusion Chemotherapy in Advanced Pancreatic Cancer: A Comprehensive Review
por: Laface, Carmelo, et al.
Publicado: (2022) -
A Case of Purpura Annularis Telangiectodes of Majocchi after Anti-SARS-CoV-2 Pfizer-BioNTech Vaccine: Is There an Association?
por: Ambrogio, Francesca, et al.
Publicado: (2022) -
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
por: Laface, Carmelo, et al.
Publicado: (2023) -
Immunotherapy and Pancreatic Cancer: A Lost Challenge?
por: Laface, Carmelo, et al.
Publicado: (2023)